Novavax and Sanofi announced licensing agreement to co-commercialize COVID-19 vaccine and novel COVID-19-influenza combination vaccines
On May 10, 2024, Novavax announced that it had entered into a co-exclusive licensing agreement with Sanofi. The…
Novavax’s updated COVID-19 vaccine received Emergency Use Authorization in the Republic of Korea
On Nov. 29, 2023, Novavax’s partner, SK bioscience, announced that Novavax’s updated COVID-19 vaccine (NVX-CoV2601) had received Emergency…
Novavax Nuvaxovid COVID-19 vaccine approved in South Korea as an adult booster
On Jan. 18, 2023, Novavax announced that partner SK bioscience had received expanded manufacturing and marketing approval from…
Novavax and SK bioscience filed post approval change application in South Korea for Nuvaxovid COVID-19 vaccine as booster in adults
On Oct. 10, 2022, Novavax announced that partner, SK bioscience, had submitted a Post Approval Change Application to…
Novavax announced expanded agreement with SK bioscience to manufacture COVID-19 vaccine with Omicron variant
On Jul. 19, 2022, Novavax announced that it had signed agreements with its partner, SK bioscience, for the…
European Medicines Agency approved SK bioscience as supplier of Novavax Nuvaxovid COVID-19 vaccine
On Jul. 7, 2022, Novavax announced that the European Commission had approved a variation to allow SK bioscience…
South Korea Ministry of Food and Drug Safety approved Novavax COVID-19 vaccine
On Jan. 12, 2022, Novavax and SK bioscience, a vaccine business subsidiary of Korea-based SK Group, announced that…
Moderna announced supply agreement with South Korea for additional 20 million doses of COVID-19 vaccine
On Dec. 27, 2021, Moderna announced a revised supply agreement with the government of South Korea for 20…
Novavax announced submission of Biologics License Application in South Korea for approval of NVX-CoV2373
On Nov. 15, 2021, Novavax and SK bioscience announced submission of a Biologics License Application (BLA) for Novavax’…
Humanigenï¾’s partner in South Korea received pproval to conduct phase 1 study of lenzilumab
On Jul. 21, 2021, Humanigen announced its development and commercialization partners for South Korea and the Philippines, Telcon…
Moderna and Samsung Biologics announced agreement for manufacturing of Moderna’s COVID-19 vaccine
On May 22, 2021, Moderna and Samsung Biologics announced a Manufacturing Services and Supply Agreement in which Samsung…
Ministry of Food and Drug Safety of South Korea authorized Moderna’s COVID-19 vaccine
On May 21, 2021, Moderna announced that the Ministry of Food and Drug Safety of South Korea (MFDS)…
Novavax announced expanded agreement with SK Bioscience for 40 million doses of COVID-19 vaccine for South Korea
On Feb. 15, 2021, Novavax and SK Bioscience announced an expanded collaboration and license agreement. In addition to…
Oxford Immunotec entered MOU with Green Cross to market T-SPOT Discovery SARS-CoV-2 Kit in South Korea
On Feb. 8, 2021, Oxford Immunotec announced it had entered into an MOU with Green Cross Medical to…
Moderna confirmed 40 million COVID-19 vaccine dose supply agreement with Republic of Korea
On Dec. 31, 2020, Moderna confirmed it had entered into a supply agreement with the government of the…
Moderna confirmed discussions with government of South Korea to supply 40 million doses of COVID-19 vaccine
On Dec. 29, 2020, Moderna confirmed that the Company was engaged in discussions with the government of South…
Humanigen executed licensing agreement for Lenzilumab in COVID-19 for South Korea and the Philippines
On Nov. 3, 2020, Humanigen announced the execution of its first licensing transaction in the Asia-Pacific Region with…
Novavax and SK bioscience announced collaboration for Novavax COVID-19 vaccine candidate
On Aug. 13, 2020, Novavax and SK bioscience announced a development and supply agreement for the antigen component…
INOVIO and IVI Partnered with Seoul National University Hospital to start phase 1/2 clinical trial of COVID-19 DNA vaccine (INO-4800) in South Korea
On Jun. 4, 2020, INOVIO and Seoul National University Hospital announced a partnership to start a Phase 1/2…
IVI, INOVIO, and KNIH partner with CEPI in phase 1/2 clinical trial of INOVIO’s COVID-19 DNA vaccine in South Korea
On Apr. 16, 2020, the International Vaccine Institute (IVI) announced that the Coalition for Epidemic Preparedness Innovations (CEPI)…
Kleo Pharmaceuticals announced research collaboration with Green Cross LabCell to develop COVID-19-targeting allogeneic NK Cell combination therapy
On Mar. 31, 2020, Kleo Pharmaceuticals announced it had entered into a research collaboration with South Korea -based…
Oxford University launched world’s first COVID-19 government response tracker
On Mar. 25, 2020, University of Oxford researchers announced they had launched the world’s first COVID-19 government response…
Medigen Vaccines and GC Pharma collaborated to commercialize quadrivalent influenza vaccine in Taiwan
On Apr. 23, 2018, Medigen Vaccine Biologics and GC Pharma entered an exclusive distribution agreement for GCC’s quadrivalent…
Spread of avian flu noted in China, Korea, Europe
On Dec. 14, 2016, reports from China and South Korea painted a picture of spreading H5N6 avian flu…
Siberian tiger genome sequenced
On Sept. 17, 2013 researchers at the South Korea’s Personal Genomics Institute in Suwon reported the mapping of…